DMK Pharmaceuticals Corporation announced that effective June 27, 2024, Ebrahim ?Eboo? Versi, M.D., Ph.D. resigned as Chairman of the Board and as a Director of the Company. Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.

Also effective June 27, 2024, John W. Dorbin, Jr. was also separated from his role as General Counsel and Corporate Secretary of the Company. None of these resignations or separations was due to disagreement with the Company on any matter relating to the Company?s operations, policies or practices, nor were any for cause. Effective June 27, 2024, Seth Cohen, the Company?s Chief Financial officer will assume the role of Chief Restructuring Officer.